Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders

Mario Romano, Piera Viero, Sergio Cortellazzo, Tiziano Barbui, Maria Benedetta Donati, Andreina Poggi

Research output: Contribution to journalArticlepeer-review


Mitogenic activity, measured as 3H-thymidine incorporation by NIH 3T3 cells, following stimulation with platelet-rich-plasma-derived serum (PRS), platelet-poor-plasma-derived serum and platelet extract was studied in 14 patients with myeloproliferative disorders (MPD) and 7 normal subjects. Reduced mitogenic activity was found in PRS and platelet extract of patients with MPD, as compared to controls. The average levels of platelet-derived growth factor (PDGF) equivalents were as follows: 16.3 ± 7.2 pg/106 platelets in controls, 6.2 ± 2.2 pg/106 (p <0.05) platelets in patients with polycythaemia vera, 1.8 <0.4 pg/106 (p <0.01) platelets in patients with idiopathic myelofibrosis and 4.0 ± 0.8 pg/106 (p <0.05) platelets in patients with essential thrombocythaemia (Dunnett test). A reduction of intraplatelet levels of P-thromboglobulin, although not statistically significant, was found in the same patients. No apparent relation was found between the amount of PDGF equivalents and the degree of bone marrow fibrosis.

Original languageEnglish
Pages (from-to)162-168
Number of pages7
JournalPathophysiology of Haemostasis and Thrombosis
Issue number3
Publication statusPublished - 1990


  • Myelofibrosis
  • Myeloproliferative disorders
  • Platelet-derived growth factor

ASJC Scopus subject areas

  • Hematology
  • Physiology (medical)


Dive into the research topics of 'Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders'. Together they form a unique fingerprint.

Cite this